Months after ditching an auto-injected version of Opdivo (nivolumab), Bristol Myers Squibb has found success with a more traditional way to administer its oncology blockbuster—with a syringe and vial.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,